Comparison of topiramate and placebo in controlling the OCD symptoms of bipolar patients

Comparison of treatment of bipolar disorder (lithium + olanzapine + clonazepam) and placebo with a treatment regimen containing topiramate in controlling the OCD symptoms of bipolar patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012061310013N1

Enrollment

Registered

2012-10-05

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bipolar Mood Disorder. Condition 2: Obsessive-Compulsive disorder. Bipolar affective disorder, current episode hypomanic Predominantly obsessional thoughts or ruminations

Interventions

Intervention 1: 16 patient intervention group will recieve topiramate in addition to lithium,olanzapine and clonazepam for 16 weeks.Dose of lithium, olanzapine, and clonazepam will sufficient for pati

Treatment - Drugs

Placebo

16 patient intervention group will recieve topiramate in addition to lithium,olanzapine and clonazepam for 16 weeks.Dose of lithium, olanzapine, and clonazepam will sufficient for patients symptoms co

16 patients control group will recieve placebo in addition to lithium,olanzapine and clonazepam for 16 weeks.Dose of lithium, olanzapine, and clonazepam will sufficient for patients symptoms control.p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Fulfilling DSM-IV-TR criteria for bipolar mood disorder; have not Major medical problem ( cardiovascular, respiratory, renal or gastrointestinal disease); not pregnant; not alcohol or other substances abuser; scores >= 18 in Yale- Brown Obsessive Compulsive Scale questionnaire. Exclusion criteria; failure to cooperate in the ongoing project for the periodical visits; non-qualification for inclusion criteria.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obsessive-compulsive signs&symptoms in BMD patients. Timepoint: before intervention and then monthly for 4 months. Method of measurement: Yale- Brown Obsessive Compulsive Scale questionaire.	—

Secondary

Measure	Time frame
Drug side effects. Timepoint: monthly for 4 months. Method of measurement: checklist of drug side effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Sahraian, MD

Psychiatry department of Shiraz University of Medical Sciences

sahraian@sums.ac.ir+98 71 1627 9319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026